NCT06262776

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients (SIR ZOSTER)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Central Adelaide Local Health Network Incorporated · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are: 1. Are there differences in vaccination immunological responses in transplant patients on different immunosuppression regimens? 2. Are there differences in vaccination immunological responses between transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.

Conditions

• Immunosuppression
• Vaccine Response Impaired

Interventions

Type	Name	Description
BIOLOGICAL	Recombinant zoster vaccine adjuvanted (SHINGRIX)	2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.

Timeline

• Start date: 2024-03-20
• Primary completion: 2026-12-01
• Completion: 2027-12-01
• First posted: 2024-02-16
• Last updated: 2026-04-09

Locations

1 site across 1 country: Australia